GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Danaher Corp (NYSE:DHR) » Definitions » EV-to-EBITDA

Danaher (Danaher) EV-to-EBITDA

: 25.57 (As of Today)
View and export this data going back to 1986. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Danaher's enterprise value is $191,654 Mil. Danaher's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $7,496 Mil. Therefore, Danaher's EV-to-EBITDA for today is 25.57.

The historical rank and industry rank for Danaher's EV-to-EBITDA or its related term are showing as below:

DHR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.28   Med: 18.63   Max: 30.83
Current: 25.57

During the past 13 years, the highest EV-to-EBITDA of Danaher was 30.83. The lowest was 7.28. And the median was 18.63.

DHR's EV-to-EBITDA is ranked worse than
79.17% of 120 companies
in the Medical Diagnostics & Research industry
Industry Median: 15.06 vs DHR: 25.57

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-17), Danaher's stock price is $239.39. Danaher's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $6.390. Therefore, Danaher's PE Ratio for today is 37.46.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Danaher EV-to-EBITDA Historical Data

The historical data trend for Danaher's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Danaher Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.48 24.36 26.41 19.79 24.64

Danaher Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.79 19.27 19.72 21.41 24.64

Competitive Comparison

For the Diagnostics & Research subindustry, Danaher's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Danaher EV-to-EBITDA Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Danaher's EV-to-EBITDA falls into.



Danaher EV-to-EBITDA Calculation

Danaher's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=191654.396/7496
=25.57

Danaher's current Enterprise Value is $191,654 Mil.
Danaher's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $7,496 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Danaher  (NYSE:DHR) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Danaher's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=239.39/6.390
=37.46

Danaher's share price for today is $239.39.
Danaher's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.390.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Danaher EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Danaher's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Danaher (Danaher) Business Description

Address
2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, USA, 20037-1701
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in two segments--life sciences and diagnostics--after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
Executives
Jose-carlos Gutierrez-ramos officer: SVP, Chief Scientific Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Linda Filler director 2200 PENNSYLVANIA AVE NW, SUITE 800W, WASHINGTON DC 20037
Daniel Raskas officer: VP-Corporate Development 2099 PENNSYLVANIA AVENUE, NORTHWEST, WASHINGTON DC 20006
Teri List director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Joakim Weidemanis officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Walter G Lohr director DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Georgeann Couchara officer: SVP, Human Resources 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Raymond C Stevens director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Matthew Mcgrew officer: EVP & Chief Financial Officer 2200 PENNSYLVANIA AVENUE, NW, SUITE 800 W, WASHINGTON DC 20010
Jennifer Honeycutt officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Alan G Spoon director 1150 15TH ST NW, WASHINGTON DC 20071
Rainer Blair officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Feroz Dewan director C/O ARENA HOLDINGS MANAGEMENT LLC, 119 FIFTH AVENUE - 8TH FLOOR, NEW YORK NY 10003
Mitchell P Rales director, officer: Chairman of Exec. Committee 11790 GLEN ROAD, POTOMAC MD 20854
Brian W Ellis officer: Senior Vice President - GC 2200 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20037

Danaher (Danaher) Headlines